Condition: Duchenne Muscular Dystrophy · Sponsor: Italfarmaco
This is a randomised, double-blind, placebo-controlled, multicentre study to evaluate the efficacy, safety, and tolerability of givinostat in non-ambulant male paediatric (aged 9 to \<18 years) patients with DMD. 138 patients will be randomised 2:1 to givinostat or placebo and will be treated for 18 months. * Planned screening duration: approximately 4 weeks (±14 days) * Planned treatment duration: 18 months (approximately 72 weeks) * Planned follow-up duration: 4 weeks (±7 days) (for patients not participating in the long-term safety study) * Total duration of study participation: up to 83 weeks (ie, 20-21 months)
This description comes directly from the study's public registry record.
Italfarmaco Patient Advocacy · +39 02 6443 1 · patientadvocacy@italfarmacogroup.com
Always discuss trial participation with your own doctor first.
| Universitaire Ziekenhuizen Leuven | Leuven, Belgium | Recruiting |
| British Columbia Children's Hospital | Vancouver, British Columbia, Canada | Recruiting |
| The University of Western Ontario - Children's Health Research Institute | London, Ontario, Canada | Recruiting |
| University of Ottawa - Children's Hospital of Eastern Ontario | Ottawa, Ontario, Canada | Recruiting |
| University of Toronto - Holland Bloorview Kids Rehabilitation Hospital | Toronto, Ontario, Canada | Recruiting |
| Klinika dětské neurologie 2. LF, Fakultní nemocnice v Motole | Prague, Czechia | Not Yet Recruiting |
| Centre Hospitalier Régional Universitaire de Lille | Lille, France | Recruiting |
| Centre hospitalier universitaire - Hôpitaux de Marseille | Marseille, France | Recruiting |
| Hôpital Armand-Trousseau - I-Motion | Paris, France | Recruiting |
| Charite-Universitaetsmedizin Berlin | Berlin, Germany | Recruiting |
| Universitätsklinikum Essen Kinder-und Jugendmedizin Neuropadiatrie | Essen, Germany | Not Yet Recruiting |
| Universitaetsklinikum Freiburg | Freiburg im Breisgau, Germany | Recruiting |
+ 17 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05933057